Literature DB >> 11135501

The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates.

V Tomasino, A J Swanson, J Nolan, H I Shuman.   

Abstract

The Key Extended Entry Program (KEEP) is the only known methadone treatment program for incarcerated opiate-dependent inmates in the United States. Initiated in 1987, KEEP performs approximately 18,000 detoxifications and 4,000 admissions for methadone treatment per year. Of those methadone treatment patients discharged to the community, mostly to outpatient KEEP programs, 74-80% report to their designated program. Recidivism rates reveal that 79% of KEEP patients were incarcerated again only once or twice during a recent 11-year period. Finally, KEEP data point to the importance of dedicating slots in the community for released inmates and maintaining them on sufficient blocking doses to eliminate the craving for heroin. About 6% of KEEP patients, some with mental illness have a high incidence of recidivism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135501

Source DB:  PubMed          Journal:  Mt Sinai J Med        ISSN: 0027-2507


  33 in total

1.  Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.

Authors:  Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer
Journal:  JAMA Intern Med       Date:  2014-05       Impact factor: 21.873

2.  Attitudes and practices regarding the use of methadone in US state and federal prisons.

Authors:  Josiah D Rich; Amy E Boutwell; David C Shield; R Garrett Key; Michelle McKenzie; Jennifer G Clarke; Peter D Friedmann
Journal:  J Urban Health       Date:  2005-05-25       Impact factor: 3.671

Review 3.  Managing HIV/AIDS in correctional settings.

Authors:  Sandra A Springer; Frederick L Altice
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

Review 4.  HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response.

Authors:  Theodore M Hammett
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

5.  Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention.

Authors:  R Douglas Bruce; Rebecca A Schleifer
Journal:  Int J Drug Policy       Date:  2008-01-15

6.  Developing and Implementing a New Prison-Based Buprenorphine Treatment Program.

Authors:  Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Terrence T Fitzgerald
Journal:  J Offender Rehabil       Date:  2010-02

7.  Why don't out-of-treatment individuals enter methadone treatment programmes?

Authors:  James A Peterson; Robert P Schwartz; Shannon Gwin Mitchell; Heather Schacht Reisinger; Sharon M Kelly; Kevin E O'Grady; Barry S Brown; Michael H Agar
Journal:  Int J Drug Policy       Date:  2008-09-20

Review 8.  Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment.

Authors:  Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2011-08       Impact factor: 5.691

9.  A Randomized Clinical Trial of Methadone Maintenance for Prisoners: Prediction of Treatment Entry and Completion in Prison.

Authors:  Michael S Gordon; Timothy W Kinlock; Kathryn A Couvillion; Robert P Schwartz; Kevin O'Grady
Journal:  J Offender Rehabil       Date:  2012-05-01

10.  A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kevin E O'Grady
Journal:  Addiction       Date:  2008-08       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.